4536
Santen Pharmaceutical Co., Ltd.
2026/02/05
For the third quarter of the fiscal year ending March 2026, revenue was JPY 210.8 billion (5.4% YoY decline), operating income was JPY 28.2 billion (19.8% YoY decline), and net income attributable to owners of the parent for the quarter was JPY 21.8 billion (20.6% YoY decline).
